Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.4.1419

Complementary and Alternative Medicine Use among Cancer Patients at the End of Life: Korean National Study  

Choi, Jin-Young (National Cancer Control Institute, National Cancer Center)
Chang, Yoon-Jung (National Cancer Control Institute, National Cancer Center)
Hong, Young-Seon (Department of Medicine, Kangnam St. Mary's Hospital, the Catholic University of Korea)
Heo, Dae-Seog (Seoul National University hospital and College of Medicine)
Kim, Sam-Yong (Division of Hematooncology, Department of Internal Medicine, Chungnam University Hospital)
Lee, Jung-Lim (Department of Internal Medicine, Fatima Hospital)
Choi, Jong-Soo (Department of Hemato-oncology, Ulsan University College of Medicine)
Kang, Ki-Mun (Department of Radiation Oncology, Gyeong Sang National University Hospital)
Kim, Si-Young (Department of Medical Oncology & Hematology, Kyunghee University Hospital)
Jeong, Hyun-Sik (Department of Internal Medicine, Good Samaritan Hospital)
Lee, Chang-Geol (Department of Radiation Oncology, Yonsei University College of Medicine)
Choi, Youn-Seon (Department of Family Medicine, Korea University College of Medicine)
Lim, Ho-Yeong (Division of Hematology-oncology, Department of Internal Medicine, Samsung Medical Center)
Yun, Young-Ho (Seoul National University hospital and College of Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.4, 2012 , pp. 1419-1424 More about this Journal
Abstract
Objectives: To investigate in depth the use of complementary and alternative medicines (CAMs) by cancer patients at the end-of-life (EOL) and how they communicate with physicians about them. Design and location: In 17 hospitals in Korea between January and December 2004 we identified 4,042 families of cancer patients. Results: The prevalence of CAM use among cancer patients at the EOL was 37.0%, and 93.1% had used pharmacologic types of agents. The most frequent motive for CAM use was the recommendation of friends or a close relative (53.4%) or a physician (1.6%). Only 42.5% discussed CAM use with their physicians. Satisfaction with CAMS was recalled for 37.1%. The most common reason given for that satisfaction was improvement of emotional or physical well-being, while ineffectiveness was the most common reason given for dissatisfaction. The average cost of CAM during the last month of life was $US 900. CAM use was associated with longer disease periods, primary cancers other than liver, biliary, and pancreatic, and need of support from physicians or religion. Conclusions: CAM use among cancer patients at the EOL was common, not discussed with physicians, and associated with expectation of cure. Expectations were generally unmet while the treatments were a financial burden. Further studies evaluating the effects of CAM at the EOL and factors that enhance communication with the physician are needed.
Keywords
Complementary and alternative medicine; end of life; Korean cancer patients;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ang-Lee MK, Moss J, Yuan CS (2001). Herbal medicines and perioperative care. JAMA, 286, 208-16.   DOI   ScienceOn
2 Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999). Use of alternative medicine by women with early-stage breast cancer. N Engl J Med, 340, 1733-9.   DOI
3 Downer SM, Cody MM, McCluskey P, et al (1994). Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ, 309, 86- 9.   DOI
4 Ernst E (1998). Harmless herbs? A review of the recent literature. Am J Med, 104, 170-8.   DOI
5 Fernandez CV, Stutzer CA, MacWilliam L, et al (1998). Alternative and complementary therapy use in pediatric oncology patients in British Columbia: prevalence and reasons for use and nonuse. J Clin Oncol, 16, 1279-86.
6 Hyodo I, Amano N, Eguchi K, et al (2005). Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol, 23, 2645-54.
7 Kao GD, Devine P (2000). Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer, 88, 615-9.   DOI
8 Lafferty WE, Downey L, McCarty RL, et al (2006). Evaluating CAM treatment at the end of life: a review of clinical trials for massage and meditation. Complement Ther Med, 14, 100-12.   DOI
9 Lerner IJ, Kennedy BJ (1992). The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin, 42, 181-91.   DOI   ScienceOn
10 Martin-Facklam M, Kostrzewa M, Schubert F, et al(2002). Quality markers of drug information on the Internet: an evaluation of sites about St. John's wort. Am J Med, 113, 740-5.   DOI
11 McEachrane-Gross FP, Liebschutz JM, Berlowitz D (2006). Use of selected complementary and alternative medicine (CAM) treatments in veterans with cancer or chronic pain: a cross-sectional survey. BMC Complement Altern Med, 6, 34.   DOI
12 McPherson CJ, Addington-Hall JM (2003). Judging the quality of care at the end of life: can proxies provide reliable information? Soc Sci Med, 56, 95-109.   DOI
13 Molassiotis A, Fernandez-Ortega P, Pud D, et al (2005). Complementary and alternative medicine use in colorectal cancer patients in seven European countries. Complement Ther Med, 13, 251-7.   DOI
14 Morris KT, Johnson N, Homer L, et al (2000). A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg, 179, 407-11.   DOI
15 Munstedt K, Kirsch K, Milch W, et al (1996). Unconventional cancer therapy--survey of patients with gynaecological malignancy. Arch Gynecol Obstet, 258, 81-8.
16 Navo MA, Phan J, Vaughan C, et al (2004). An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol, 22, 671-7.   DOI   ScienceOn
17 Newell S, Sanson-Fisher RW (2000). Australian oncologists' self-reported knowledge and attitudes about nontraditional therapies used by cancer patients. Med J Aust, 172, 110-3.
18 Pan CX, Morrison RS, Ness J, et al (2000). Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage, 20, 374-87.   DOI
19 Richardson MA (1999). Research of complementary/ alternative medicine therapies in oncology: promising but challenging. J Clin Oncol, 17, 38-43.
20 Richardson MA, Masse LC, Nanny K, et al (2004). Discrepant views of oncologists and cancer patients on complementary/alternative medicine. Support Care Cancer, 12, 797-804.   DOI
21 Richardson MA, Sanders T, Palmer JL, et al(2000). Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol, 18, 2505-14.
22 Richardson MA, Straus SE (2002). Complementary and alternative medicine: opportunities and challenges for cancer management and research. Semin Oncol, 29, 531- 45.   DOI
23 Risberg T, Lund E, Wist E, et al (1995). The use of non-proven therapy among patients treated in Norwegian oncological departments. A cross-sectional national multicentre study. Eur J Cancer, 31A, 1785-9.
24 Risberg T, Vickers A, Bremnes RM, et al (2003). Does use of alternative medicine predict survival from cancer? Eur J Cancer, 39, 372-7.   DOI   ScienceOn
25 Robotin MC, Penman AG (2006). Integrating complementary therapies into mainstream cancer care: which way forward? Med J Aust, 185, 377-9.
26 Schraub S (2000). Unproven methods in cancer: a worldwide problem. Support Care Cancer, 8, 10-5.
27 Sollner W, Maislinger S, DeVries A, et al(2000). Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer, 89, 873-80.   DOI
28 Sollner W, Zingg-Schir M, Rumpold G, et al(1998). Need for supportive counselling--the professionals' versus the patients' perspective. A survey in a representative sample of 236 melanoma patients. Psychother Psychosom, 67, 94-104.   DOI
29 Steinhauser KE, Christakis NA, Clipp EC, et al(2000). Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA, 284, 2476-82.   DOI
30 Spiegel D, Bloom JR, Kraemer HC, et al(1989). Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet, 2, 888-91.
31 Swisher EM, Cohn DE, Goff BA, et al (2002). Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol, 84, 363-7.   DOI   ScienceOn
32 Tas F, Ustuner Z, Can G, et al (2005). The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncol, 44, 161-7.   DOI
33 Tasaki K, Maskarinec G, Shumay DM, et al(2002). Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives. Psychooncology, 11, 212-20.   DOI
34 Tilden VP, Drach LL, Tolle SW (2004). Complementary and alternative therapy use at end-of-life in community settings. J Altern Complement Med, 10, 811-7.   DOI
35 Verhoef MJ, Balneaves LG, Boon HS, et al(2005). Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther, 4, 274-86.   DOI
36 Vitetta L, Sali A (2006). Complementary medicine in palliative care. Aust Fam Physician, 35, 783.
37 Wall L (2003). Fish oil supplementation in patients with advanced cancer. J Clin Oncol, 21, 3545; author reply -6.   DOI
38 WHO (2007). WHO traditional medicine strategy 2002-2005.
39 Wilkinson S, Gomella LG, Smith JA, et al (2002). Attitudes and use of complementary medicine in men with prostate cancer. J Urol, 168, 2505-9.   DOI